BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21273581)

  • 21. Epidermal growth factor receptor biology in head and neck cancer.
    Kalyankrishna S; Grandis JR
    J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of resistance to EGFR inhibitors in head and neck cancer.
    Cooper JB; Cohen EE
    Head Neck; 2009 Aug; 31(8):1086-94. PubMed ID: 19378324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer.
    Wang SJ; Bourguignon LY
    Arch Otolaryngol Head Neck Surg; 2006 Jul; 132(7):771-8. PubMed ID: 16847188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance of oral squamous cell carcinoma cells to cetuximab is associated with EGFR insensitivity and enhanced stem cell-like potency.
    Ohnishi Y; Minamino Y; Kakudo K; Nozaki M
    Oncol Rep; 2014 Aug; 32(2):780-6. PubMed ID: 24926885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidermal growth factor receptor inhibitors enhance susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells.
    Iwase M; Takaoka S; Uchida M; Yoshiba S; Kondo G; Watanabe H; Ohashi M; Nagumo M
    Oral Oncol; 2008 Apr; 44(4):361-8. PubMed ID: 17689285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma.
    Nozawa H; Tadakuma T; Ono T; Sato M; Hiroi S; Masumoto K; Sato Y
    Cancer Sci; 2006 Oct; 97(10):1115-24. PubMed ID: 16984384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of ten newly-derived human head and neck squamous carcinoma cell lines with special reference to c-erbB proto-oncogene expression.
    O-Charoenrat P; Rhys-Evans P; Eccles S
    Anticancer Res; 2001; 21(3B):1953-63. PubMed ID: 11497283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implications of EGFR inhibition in ovarian cancer cell proliferation.
    Bull Phelps SL; Schorge JO; Peyton MJ; Shigematsu H; Xiang LL; Miller DS; Lea JS
    Gynecol Oncol; 2008 Jun; 109(3):411-7. PubMed ID: 18423824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression.
    Gurtner K; Deuse Y; Bütof R; Schaal K; Eicheler W; Oertel R; Grenman R; Thames H; Yaromina A; Baumann M; Krause M
    Radiother Oncol; 2011 Jun; 99(3):323-30. PubMed ID: 21665304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma.
    Hama T; Yuza Y; Saito Y; O-uchi J; Kondo S; Okabe M; Yamada H; Kato T; Moriyama H; Kurihara S; Urashima M
    Oncologist; 2009 Sep; 14(9):900-8. PubMed ID: 19726454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines.
    Bradford CR; Zhu S; Ogawa H; Ogawa T; Ubell M; Narayan A; Johnson G; Wolf GT; Fisher SG; Carey TE
    Head Neck; 2003 Aug; 25(8):654-61. PubMed ID: 12884349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
    Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
    Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transforming growth factor alpha stimulation of mucosal tissue cultures from head and neck squamous cell carcinoma patients increases chemoresistance to cisplatin.
    Baumeister P; Reiter M; Schwenk-Zieger S; Harréus U
    Chemotherapy; 2010; 56(4):268-74. PubMed ID: 20693797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.
    Amador ML; Oppenheimer D; Perea S; Maitra A; Cusatis G; Iacobuzio-Donahue C; Baker SD; Ashfaq R; Takimoto C; Forastiere A; Hidalgo M
    Cancer Res; 2004 Dec; 64(24):9139-43. PubMed ID: 15604284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature.
    Rabinowits G; Haddad RI
    Oral Oncol; 2012 Nov; 48(11):1085-9. PubMed ID: 22840785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Restoration of BRAK / CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma.
    Ozawa S; Kato Y; Ito S; Komori R; Shiiki N; Tsukinoki K; Ozono S; Maehata Y; Taguchi T; Imagawa-Ishiguro Y; Tsukuda M; Kubota E; Hata R
    Cancer Sci; 2009 Nov; 100(11):2202-9. PubMed ID: 19673887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.
    Baba Y; Maeda T; Suzuki A; Takada S; Fujii M; Kato Y
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab.
    Kondo N; Ishiguro Y; Kimura M; Sano D; Fujita K; Sakakibara A; Taguchi T; Toth G; Matsuda H; Tsukuda M
    Oncol Rep; 2008 Aug; 20(2):373-8. PubMed ID: 18636200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.
    Hartmann S; Seher A; Brands RC; Linz C; Lessner G; Böhm H; Kübler AC; Müller-Richter UD
    J Craniomaxillofac Surg; 2014 Oct; 42(7):1322-8. PubMed ID: 24780353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.